Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(NASDAQ:RARE), NOVATO, Calif., May 20, 2025 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,805 restricted stock units of the company's common stock to 20 newly hired non-executive officers of the company. The […]